Nordic Nanovector
Kjelsåsveien 168 B
Oslo
0884
Tel: 47-22-18-33-01
Fax: 47-22-58-00-07
Website: http://www.nordicnanovector.no/
Email: mail@nordicnanovector.no
343 articles about Nordic Nanovector
-
Nordic Nanovector - Completion of annual general meeting
6/28/2023
Reference is made to the stock exchange announcement made by Nordic Nanovector ASA on 6 June 2023 regarding the Company's acquisition of Thor Medical AS, with approval of the Transaction from the Company's annual general meeting as one of the closing conditions.
-
Nordic Nanovector - Appointment of Alf Bjørseth as CEO
6/28/2023
Reference is made to the stock exchange announcement made earlier by Nordic Nanovector ASA, where the Company announced, among other things, that the annual general meeting had elected new board members to the board of directors, including electing former interim CFO & CEO Ludvik Sandnes as new chairman.
-
Nordic Nanovector - Notice of Annual General Meeting on 28 June 2023
6/7/2023
Notice is given that the Annual General Meeting of Nordic Nanovector ASA will be held on 28 June 2023, at 14:00 hours CEST at Advokatfirmaet CLP, Sommerrogata 13-15, 0255 Oslo.
-
Nordic Nanovector announces agreement to acquire Thor Medical, an emerging producer of alpha-emitters for radiopharmaceuticals to treat cancer
6/6/2023
Nordic Nanovector ASA and Thor Medical AS, a privately held company focused on the production of alpha-emitting radionuclides for cancer treatment, announce that they have entered into a definitive share exchange agreement to combine the two companies in an all-share transaction.
-
Nordic Nanovector Publishes Data from the PARADIGME Phase 2 Clinical Trials with Betalutin® on European Clinical Trials Database
4/18/2023
Nordic Nanovector ASA announces that full results from its Phase 2 clinical trials of Betalutin® in resistant/refractory indolent non-Hodgkin's lymphoma have been published at EudraCT, the European Union Drug Regulating Authorities Clinical Trials Database of the European Union.
-
Nordic Nanovector - Annual General Meeting Postponed
3/31/2023
The Board of Directors of Nordic Nanovector ASA has decided to postpone the upcoming Annual General Meeting, which was originally scheduled for 26 April.
-
Nordic Nanovector - Annual and Remuneration Reports Approved
3/23/2023
On 22 March 2023, the Board of Directors of Nordic Nanovector ASA approved the Company's financial statements for 2022.
-
Nordic Nanovector ASA Results for the Second Half and Full Year 2022
2/28/2023
Nordic Nanovector ASA announces its results for the second half and full year 2022. A presentation by Nordic Nanovector's interim CEO & CFO, Ludvik Sandnes will be held in-person in Oslo and webcast live beginning at 8:30am CET - details below.
-
Nordic Nanovector ASA: Invitation to Second Half and Full Year 2022 Results Presentation and Webcast
2/21/2023
Nordic Nanovector ASA announces that it will report its results for the second half and full year 2022 on Tuesday, 28 February 2023.
-
Nordic Nanovector ASA announces that Ludvik Sandnes has been appointed interim Chief Executive Officer (CEO) and Chief Financial Officer (CFO)
1/31/2023
Nordic Nanovector ASA ("Nordic Nanovector" or the "Company") announces that Ludvik Sandnes, former Chairperson of Nordic Nanovector, has been appointed interim Chief Executive Officer (CEO) and Chief Financial Officer (CFO) of the Company as from 1 February 2023.
-
Nordic Nanovector ASA: Extraordinary General Meeting held - Jan 03, 2023
1/3/2023
An Extraordinary General Meeting of Nordic Nanovector ASA was held on 3 January 2023 in Oslo, Norway.
-
Nordic Nanovector ASA - Notice of Extraordinary General Meeting on 3 January 2023
12/13/2022
Nordic Nanovector ASA's largest shareholder North Energy ASA, that now holds 11,518,448 shares in the Company, has requested that the Board of Directors calls for an Extraordinary General Meeting in accordance with the Norwegian Public Limited Liability Companies Act §5-7.
-
Nordic Nanovector update following shareholder vote against proposed merger with APIM Therapeutics
12/9/2022
Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company") today announces an update following the Extraordinary General Meeting held on 1 December at which the proposed merger transaction with APIM Therapeutics AS ("APIM") did not obtain a sufficient majority of votes and was therefore voted down.
-
Nordic Nanovector ASA: Extraordinary General Meeting held - December 1, 2022
12/1/2022
An Extraordinary General Meeting (the "EGM") of Nordic Nanovector ASA (the "Company") (OSE: NANOV) was held today on 1 December 2022 in Oslo, Norway.
-
Nordic Nanovector Launches Dedicated Area on its Website in Norwegian for Information on the Proposed Merger with APIM Therapeutics
11/25/2022
Nordic Nanovector ASA has today launched a new dedicated area on its website ( www.nordicnanovector.com ) with information in Norwegian for shareholders relating to its proposed merger with APIM Therapeutics ("APIM").
-
Nordic Nanovector: Invitation to webcast regarding proposed merger with APIM Therapeutics
11/23/2022
Nordic Nanovector ASA will host a webcast, including a question and answers session on Thursday, November 24 at 4.30 P.M. CET.
-
Nordic Nanovector comment on Proposed Merger with APIM Therapeutics
11/21/2022
Nordic Nanovector ASA desires to share more information with the Company's shareholders about the proposed merger between the Company and APIM Therapeutics.
-
Nordic Nanovector Highlights Novel Humanized Anti-CD37 Therapeutic Antibody Candidates for B-cell Malignancies or B-cell-driven Autoimmune Disorders at ASH Annual Meeting
11/3/2022
Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company") announces the progress it has made in designing and developing a portfolio of novel and potent humanized anti-CD37 monoclonal antibodies with potential for treating B-cell malignancies or B-cell-driven autoimmune disorders.
-
Nordic Nanovector consolidates Board to conserve resources while it explores strategic options
9/15/2022
Nordic Nanovector ASA announces that following the decisions to discontinue the PARADIGME study for its lead asset Betalutin®, restructure the company and appoint Carnegie Investment Bank to explore strategic options three members of the Company's Board have decided to step down.
-
Nordic Nanovector ASA Results for the Second Quarter and First Half 2022
8/31/2022
Nordic Nanovector ASA announces its results for the second quarter and first half 2022.